Status:
UNKNOWN
Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Neuroblastoma
Eligibility:
All Genders
1-18 years
Phase:
PHASE2
Brief Summary
To date, no curative option exists for patients with relapsed or refractory stage IV neuroblastoma after previous autologous stem cell transplantation. Our preliminary results of RIC allo-HSCT (protoc...
Detailed Description
This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+...
Eligibility Criteria
Inclusion
- High Risk Neuroblastoma
- HLA haplo-identical family donor
Exclusion
- patient with fast progressive neuroblastoma
- Lansky \< 60%
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01156350
Start Date
September 1 2011
End Date
September 1 2014
Last Update
January 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Clermont-Ferrand
Clermont-Ferrand, France, 63003